Metastatic Castrate-Resistant Prostate Cancer Treatment: Updates on Use of Darolutamide

Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.

An oncologist explains treatment selection and the systemic therapy options available for patients with metastatic castrate-resistant prostate cancer.

Dr. Karim Fizazi describes the use of next generation androgen receptor inhibitors in treatment of metastatic castrate-resistant prostate cancer.

A key opinion leader discusses impact of ADTs on brain and cognitive function in men with prostate cancer.

Karim Fizazi, MD, PhD, reviews darolutamide data in prostate cancer, including data from phase II clinical trial, ODENZA.

An expert discusses the future of metastatic castrate-resistant prostate cancer management.